Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $17

Benzinga · 05/09 17:50
Oppenheimer analyst Jeff Jones maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $19 to $17.